Drug intelligence / Profile preview

GB-6201

Development stage: Preclinical
Lead developer: G2GBio
Modality: Implantable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Small Molecules, Implantable Devices → Device-based Delivery → Drug Delivery Systems, Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems
Administration: Subcutaneous, Intramuscular

Overview

GB-6201 is a long-acting, sustained-release injectable formulation of dutasteride developed by G2G Bio for the treatment of androgenetic alopecia (male pattern baldness). Utilizing G2G Bio's proprietary InnoLAMP (Innovative Long-Acting MicroParticle) technology, the drug is encapsulated in PLGA (poly(lactic-co-glycolic acid)) microspheres to provide controlled therapeutic levels of dutasteride for one to three months from a single injection. Dutasteride is a dual inhibitor of the enzyme 5-alpha reductase (types 1 and 2), which is responsible for converting testosterone into dihydrotestosterone (DHT), the primary hormone implicated in hair follicle miniaturization. By significantly reducing DHT levels in the scalp and serum, GB-6201 aims to arrest hair loss and promote regrowth. This injectable format is intended to improve patient adherence compared to daily oral medications and potentially minimize systemic side effects.

Other names: Dutasteride sustained-release injectionG2G Bio dutasteride 1M/3M

Targets

SRD5A2 (Steroid 5-alpha-reductase type II)SRD5A1 (Steroid 5-alpha-reductase type 1)

Beyond the preview

Go deeper on GB-6201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GB-6201.

Explore the full profile